KyungDong Pharm home
Prescription Medicines

Epastine Tab.

Product Category
Antihistamines
Active Ingredients
Epinastine hydrochloride
Appearance
A white or pale yellow, round, film-coated tablet.
Reimbursement Code
648104680
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Epinastine hydrochloride (in-house specification) ----- 10mg
- Additives: Light anhydrous silicic acid, microcrystalline cellulose, magnesium stearate, Opadry white (OY-C-7000A), crospovidone

2. Effectiveness
1. Bronchial asthma
2. Allergic rhinitis
3. Hives, eczema, dermatitis, itchy skin, itchy rash, psoriasis common with itching

3. Dosage and dosage
1. Asthma, urticaria, eczema/dermatitis, itchy skin, itchy rash, psoriasis common with itching
Adults: Administer epinastine hydrochloride, 20 mg orally once a day. Increase or decrease appropriately depending on symptoms.
2. Allergic rhinitis
Adults: Administer 10 to 20 mg orally once a day. Increase or decrease appropriately depending on symptoms.

4. Precautions for use
1. Do not administer to the following patients.
Patients with hypersensitivity to this drug or its components

2. Administer with caution to the following patients.
Patients with liver disease or a history of liver disease (liver disease may worsen or recur).

3. Adverse reactions
1) Hypersensitivity reaction: If allergic reaction (e.g. rash, hives, redness), itching, swelling (face, limbs, etc.), or erythema accompanied by itching occurs, stop administration and take appropriate measures.
2) Mental nervous system: Drowsiness, fatigue, headache, rarely, dizziness, insomnia, nightmares, paralysis, and brain fog may occur.
3) Digestive system: Occasionally, nausea, stomach discomfort, dry mouth, abdominal pain, and in rare cases, loss of appetite, vomiting, feeling of heaviness in the stomach, feeling in the stomach, diarrhea, constipation, dry lips, abdominal distension, stomatitis, etc. may occur.
4) Liver: Increases in AST, ALT, γ-GTP, ALP, LDH, liver dysfunction, and jaundice may occur. Therefore, observe thoroughly and take appropriate measures, such as discontinuing administration if adverse reactions occur. Exacerbation of symptoms has been sporadically reported in patients with hepatitis and existing liver damage.
5) Kidney: In rare cases, proteinuria may occur.
6) Urinary system: In rare cases, cystitis-like symptoms such as frequent urination and hematuria and urinary retention may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration, if adverse reactions occur.
7) Circulatory system: Sometimes palpitations may occur.
8) Respiratory system: In rare cases, shortness of breath, difficulty in expectoration, and nasal congestion may occur.
9) Blood system: Unexplained decrease in platelets and rare increase in white blood cells may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if adverse reactions occur.
10) Unexplained gynecomastia, breast enlargement, rare menstrual abnormalities, burning sensation, bitter taste, decreased sense of taste, and chest pain may occur.

4. General precautions
1) Unlike bronchodilators, steroids, etc., this drug is not a drug that quickly relieves the symptoms of asthma attacks, so it is necessary to provide sufficient explanation to such patients.
2) In patients receiving long-term steroid therapy, if the steroid dose is to be reduced due to administration of this drug, it should be done gradually and under sufficient management.
3) Clinical tests on driving ability showed that this drug did not affect driving ability. Nevertheless, because this drug may cause drowsiness, patients should be advised to be careful when operating machinery or driving a car.
4) If the effect of using this drug is not confirmed, be careful not to administer it for a long period of time.
5) When administering to seasonal patients, it is advisable to consider the peak season and administer the drug immediately before the peak season and administer continuously until the end of the peak season.

5. Interaction
1) In light of preclinical results, this drug does not appear to enhance the sedative effects of sleeping pills, antihistamines, or alcohol. However, there is no clinical experience with coadministration with these drugs.
2) Unlike other antihistamines that do not have a sedative effect, this drug is mainly excreted as a non-metabolite. This drug has no or minimal interactions with CYP1A2, CYP2C9, CYP2D6, CYP2E1, and CYP3A4. Therefore, it is not expected to affect the metabolism of other drugs that are excreted dependent on CYP-450.

6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks (in pre-pregnancy or early pregnancy tests (rats), there was a decrease in the conception rate, and in organogenesis tests (rabbits), fetal lethality was confirmed at high doses.)
2) Since it has been reported in animal testing (rats) that the drug passes into breast milk, avoid administering it to lactating women, and if administration is unavoidable, stop breastfeeding.

7. Administration to children
Safety for low birth weight infants, newborns, infants and children has not been established (there is little experience with use).

8. Administration to elderly people
In elderly people, liver and kidney function often decrease, and the absorbed drug is mainly excreted by the kidneys. Therefore, regularly observe adverse reactions and clinical symptoms (rash, dry mouth, stomach discomfort, etc.), and if adverse reactions occur, take appropriate measures such as reducing the dose (10 mg/day) or stopping the drug.

9. Treatment in case of overdose
1) Symptoms: There is limited experience with overdose of this drug. As with other H1 antagonists, the possibility of prolonging the QT interval in case of overdose cannot be ruled out and thus may potentially cause arrhythmia. Although these symptoms have not been reported with this drug, ECG should be monitored in case of overdose.
2) Treatment: Induce gastric lavage and/or urination. Provide symptomatic treatment.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Pharmaceutical equivalence test information
A. The test drug Allerion tablets (Epitastine hydrochloride) (Genupharma Co., Ltd.) and the control drug Allerion tablets 10 mg (Epitastine hydrochloride) (Boehringer Ingelheim Korea Co., Ltd.) were administered orally once on an empty stomach to 55 healthy adults in a 2x2 cross-over study. Epinastine in the blood was measured, and comparative evaluation values (AUCt, Cmax) were log-transformed. When subjected to statistical processing, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
※ Table: Refer to attached document

※ This drug is manufactured using the same raw materials as Genupharma Alerion Tablets (Epitastine Hydrochloride) and the entire process is outsourced to Genupharma Co., Ltd. using the same manufacturing method.

12. Others
There are reports that when administered on an empty stomach, the blood concentration is higher than when administered after a meal (effectiveness and safety were confirmed when administered before bedtime for bronchial asthma and allergic rhinitis, and when administered after a meal for urticaria, eczema, dermatitis, skin itchiness, itchy rash, and psoriasis accompanied by itching).

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture